Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159832 | 0.95 | CYP1A2 (0.37) | CYP1A2NAAAHTTLMNAMAPK1 | |
| SCHEMBL1893345 | 0.95 | CYP1A2 (0.47) | CYP1A2NAAAHTTLMNAMAPK1 | |
| SCHEMBL4159287 | 0.89 | TLR4 (0.35) | HPGDCYP2C9 | |
| SCHEMBL504003 | 0.89 | CYP1A2 (0.41) | CYP1A2NAAAHTTLMNAMAPK1 | |
| SCHEMBL5862504 | 0.88 | HTT (0.40) | CYP1A2NAAAHTTLMNAMAPK1 | |
| SCHEMBL8975284 | 0.88 | HTT (0.40) | CYP1A2NAAAHTTLMNAMAPK1 | |
| SCHEMBL1896640 | 0.88 | HTT (0.40) | CYP1A2NAAAHTTLMNAMAPK1 | |
| SCHEMBL11290481 | 0.88 | HTT (0.40) | CYP1A2NAAAHTTLMNAMAPK1 | |
| SCHEMBL8735525 | 0.86 | CYP1A2 (0.36) | CYP1A2NAAAHTTLMNAMAPK1 | |
| SCHEMBL6278928 | 0.83 | HPGD (0.34) | CYP1A2NAAALMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105916894-A | Polymerizable compound, polymerizable composition, film and half mirror for displaying projected image | 富士胶片株式会社 | 2016-08-31 | — | — | CN | disclosed |
| US-8293146-B2 | Optical film and phase difference plate, and liquid crystal compound | FUJIFILM CORPORATION (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20090159857-A1 | OPTICAL FILM AND PHASE DIFFERENCE PLATE, AND LIQUID CRYSTAL COMPOUND | FUJIFILM CORPORATION (JP) | 2009-06-25 | — | — | US | disclosed |
| WO-2007091716-A1 | OPTICAL FILM AND PHASE DIFFERENCE PLATE, AND LIQUID CRYSTAL COMPOUND | FUJIFILM CORPORATION (JP) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090159857-A1 | OPTICAL FILM AND PHASE DIFFERENCE PLATE, AND LIQUID CRYSTAL COMPOUND | NOM1, CRYZ, CNN2 | CYP1A2 3757/4885NAAA 3924/4885HTT 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.